Microscopic yeast have been wreaking havoc in hospitals around the world—creeping into catheters, ventilator tubes, and IV lines—and causing deadly invasive infection. One culprit species, Candida auris, is resistant to many antifungals, meaning once a person is infected, there are limited treatment options. But in a recent Antimicrobial Agents and Chemotherapy study, researchers confirmed a new drug compound kills drug-resistant C. auris, both in the laboratory and in a mouse model that mimics human infection.
APX001, the prodrug of the active moiety APX001A, is currently in clinical development by Amplyx Pharmaceuticals. It works through a novel mechanism of action. Unlike other antifungal agents that poke holes in yeast cell membranes or inhibit sterol synthesis, the new drug targets an enzyme called Gwt1, which is required for anchoring critical proteins to the fungal cell wall. This means C. auris can’t grow properly and has a harder time forming drug-resistant fungal biofilms that are a stubborn source of hospital outbreaks. Gwt1 is highly conserved across fungal species, suggesting the new drug could treat a broad range of fungal infections.
“The drug is first in a new class of antifungals, which could help stave off drug resistance. Even the most troublesome strains are unlikely to have developed workarounds for its mechanism of action,” said study lead Mahmoud A. Ghannoum, PhD, professor of dermatology at Case Western Reserve University School of Medicine and director of the Center for Medical Mycology at Case Western Reserve University and University Hospitals Cleveland Medical Center.
In the new study, Ghannoum’s team tested the drug against 16 different C. auris strains, collected from infected patients in Germany, Japan, South Korea, and India. When they exposed the isolates to the new drug, they found it more potent than nine other currently available antifungals. According to the authors, the concentration of study drug needed to kill C. auris growing in laboratory dishes was “eight-fold lower than the next most active drug, anidulafungin, and more than 30-fold lower than all other compounds tested.”
The researchers also developed a new mouse model of invasive C. auris infection for the study. Said Ghannoum, “To help the discovery of effective drugs it will be necessary to have an animal model that mimics this infection. Our work helps this process in two ways: first we developed the needed animal model that mimics the infection caused by this devastating yeast, and second, we used the developed model to show the drug is effective in treating this infection.”
Ghannoum studied immunocompromised mice infected with C. auris via their tail vein—similar to very sick humans in hospitals who experience bloodstream infections. Infected mice treated with APX001 and anidulafungin had significant reductions in kidney and lung fungal burden two days post-treatment, compared to control animals. APX001 also significantly decreased fungal burden in the brain, consistent with brain penetration, whereas reduction with anidulafungin did not reach significance. The results suggest the new drug could help treat even the most invasive infections.
According to Ghannoum, the most exciting element of the study is that it brings a promising antifungal one step closer to patients. It helps lay the foundation for phase 2 clinical trials that study that study the safety and efficacy of new drugs in patients with fungal infections. There is an urgent need for such studies, as C. auris infection has become a serious threat to healthcare facilities worldwide—and resistance to commercially available antifungal drugs is rising.
“Limited treatment options calls for the development of new drugs that are effective against this devastating infection,” Ghannoum said. “We hope that we contributed in some way towards the development of new drugs.”
The Latest on: Antifungal
via Google News
The Latest on: Antifungal
- The fungi forager: Franklin man develops a passion for wild mushroomson September 4, 2019 at 8:07 am
That didn’t work out so well, probably mostly because mountain laurel is a potent antifungal. That makes it the perfect material for crafting decay-resistant handrails, but as a base for mushroom ...
- Antifungal Drugs Market 2019 - Trends and Competitive Landscape Outlook Expand With Top Key Companies Till 2026on September 4, 2019 at 6:48 am
Sep 04, 2019 (Global QYResearch via COMTEX) -- The global Antifungal Drugs market studies the overall dynamics and trends of the market in terms of various segments and regional outlook for the period ...
- Cidara gets $30M upfront, possibly hundreds of millions more, for its antifungal drugon September 4, 2019 at 6:08 am
San Diego’s Cidara Therapeutics will get $30 million upfront and as much as $568 million, plus double-digit royalties in a deal to bring its flagship antifungal drug to market. The agreement with ...
- Antifungal Treatment Market to register a high value CAGR of 4.61% By 2023on September 4, 2019 at 5:15 am
The global antifungal treatment market is predicted to touch USD 19,558.0 million at a 4.61% CAGR over the forecast period (2017-2023), states the latest Market Research Future (MRFR) report. Fungal ...
- Cidara Rallies On Development Deal For Lead Antifungal Medicationon September 3, 2019 at 12:22 pm
Mundipharma is to make a $9-million equity investment in Cidara. Rezafungin is a novel, once-weekly echinocandin antifungal being developed for the first-line treatment of candidemia and invasive ...
- Canadian Cannabis Strains for People Who Love Limoneneon September 3, 2019 at 11:38 am
Strains with this terpene are said to improve mood, washing away stress. Limonene isolated by itself has been proven to be a great antifungal and antibacterial agent (hence the cleaning products). If ...
- Cidara Therapeutics and Mundipharma Form Strategic Partnership to Develop and Commercialize Rezafunginon September 3, 2019 at 3:00 am
Rezafungin is a novel, once-weekly echinocandin antifungal being developed for the first-line treatment of candidemia and invasive candidiasis as well as for the prophylaxis of invasive fungal ...
- Antifungal Drugs Market Value to Attain $17.72 Billion by 2023 | Studyon August 30, 2019 at 10:08 am
Surge in the prevalence of fungal infections along with rise in the awareness levels pertaining to myriad fungal infections facilitate the growth of the global antifungal drugs market. Furthermore, ...
- Glenmark recalls 31,000 tubes of antifungal creamon August 26, 2019 at 9:31 am
Glenmark Pharmaceuticals is recalling 31,224 tubes of an antifungal cream due to customer complaints about its texture. The affected product is the drugmaker's clotrimazole and betamethasone ...
via Bing News